OUR QUEST

Advancing medicines
Solving therapeutic problems
Improving lives

18 years. 2+ billion doses and counting.

Our pipeline of medicines aims to overcome barriers that patients face with existing treatment options and provide new paradigms for treating critical and complex conditions.1

See our pipeline

OUR QUEST

Deliver clinical and therapeutic advances

2B+ doses consumed. 200+ patents provide strong intellectual property.

Aquestive is the worldwide leader in delivering trusted, quality medications on oral film. Every medicine is different, so Aquestive follows a drug-by-drug approach for harnessing PharmFilm® technology to achieve target product profiles and clinical improvement goals.

Learn about PharmFilm® technology

Pipeline

Aquestive Therapeutics is the undisputed leader in developing and delivering medications via film, through our proprietary PharmFilm® technology. We’ve used our expertise to create a robust, proprietary, and complex molecule portfolio.

Learn about the medicines we’re reinventing to improve treatment options for patients.

See our pipeline

Reimagining How to Treat Anaphylaxis

Anaphylaxis is a serious systemic hypersensitivity reaction. Aquestive is developing AQST-109, a sublingual film that, if approved by the FDA, will allow patients to simply place a dissolvable strip, approximately the size and weight of a postage stamp, under the tongue to provide rapid delivery of epinephrine when it is needed.

Find out how

Innovative Drug Delivery

PharmFilm® is a versatile, high-performance drug delivery technology that can be uniquely tailored to achieve a desired product profile with optimized absorption, bioavailability, and onset of action.

See how Aquestive is changing drug delivery to deliver meaningful clinical and therapeutic advances.

Learn about PharmFilm® technology
Microscope

Advancing medicines

Light bulb shining

Solving therapeutic problems

Group of 3 people

Improving lives

Aquestive is a pharmaceutical company aiming to solve patients’ problems by advancing current standards of care through simplifying complex delivery methods. Aquestive is developing orally administered products to provide novel alternatives to invasive and inconvenient standard of care therapies.  Our focus is to improve medications and outcomes for patients with central nervous system (CNS) conditions and severe allergies, including anaphylaxis.

Our success is proven

2B+

PharmFilm® doses consumed by patients

200+

Worldwide patents

4

Continents where our products are sold

We work hand-in-hand with our partners to address their toughest challenges—enhancing existing molecules and providing a simplified development platform for new ones. We have comprehensive capabilities to advance medicines from pipeline to market. Partners can rely on our scientific and regulatory expertise, integrated development capabilities, and world-class clinical and commercial manufacturing operations. More than 2 billion commercial doses have been delivered with our PharmFilm® technology.

News Articles

Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study

Time to maximum blood concentration (median Tmax) for Anaphylm was 10 minutes with a range of 5 to 20 minutes Early drug exposure at 10 minutes (partial area under the curve, or pAUC 0-10min ) for Anaphylm was similar to Auvi-Q® (epinephrine injection) auto-injector 0.3mg and over 4 times higher

 

Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Continues to advance development of AQST-109 (epinephrine sublingual film); received FDA conditional approval of brand name Anaphylm™ Raises full year 2023 revenue and non-GAAP adjusted EBITDA guidance Reaffirms commitment to pursue early market access for Libervant™ (diazepam) Buccal Film Obtains

 

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

WARREN, N.J. , April 26, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, announced today that the management team

 

References

1. Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67–76.

2. Haut SR, Seinfeld S, Pellock J. Benzodiazepine use in seizure emergencies: a systematic review. Epilepsy Behav. 2016;63:109–117.

Please complete this form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-941-1900.
  • This field is for validation purposes and should be left unchanged.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

  • To subscribe to receive marketing updates about diazepam buccal film and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

  • To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete this form:

  • To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”